NASDAQ: ELOX
- Last Close 4.78
- Sector Healthcare
- Industry Biotechnology
- Investment Style Small Value
- Day Range 4.53 – 5.09
- Year Range 1.70 – 10.90
- Market Cap 14.0073 Mil
- Volume / Avg 39,888.0 / 950,236.4
- Price / Sales —
- Price / Book —
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis ELOX
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile ELOX
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Eloxx Pharmaceuticals Inc
XNAS: ELOX
| Translate Bio Inc
XNAS: TBIO
| Relmada Therapeutics Inc
XNAS: RLMD
| Unity Biotechnology Inc
XNAS: UBX
| |
Price
| 4.58 | — | 2.99 | 1.86 |
Currency
| USD | — | USD | USD |
Change
| −$0.20 (4.18%) | — | −$0.11 (3.55%) | −$0.12 (6.06%) |
Market Cap
| 14.01 Mil | — | 90.00 Mil | 27.16 Mil |
Industry
| Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Eloxx Pharmaceuticals Inc Stock
No. ELOX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
ELOX’s market cap is 14.01 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
ELOX’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
ELOX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare ELOX’s historical performance against its industry peers and the overall market.